Former HHS medical chief Dr. Vanila Singh is hopeful that the COVID vaccine process will improve.
More than 92 million doses of the COVID-19 vaccine have been administered in the United States as of Monday, according to the latest data from the Centers for Disease Control and Prevention.
There are currently three vaccines approved by the CDC and the Food and Drug Administration for emergency use, which were manufactured by Pfizer and BioNTech, Moderna and Johnson & Johnson.
| Ticker | Safety | Last | Change | Change % |
|---|---|---|---|---|
| PFE | PFIZER INC. | 34.32 | -0.05 | -0.15% |
| BNTX | BIONTECH SE | 90.29 | -5.91 | -6.14% |
| MRNA | MODERNA, INC. | 123.47 | -8.72 | -6.60% |
| JNJ | JOHNSON & JOHNSON | 157.47 | +1.35 | + 0.86% |
Here is a summary from FOX Business of the profit that each company’s vaccine is expected to bring:
THE RELIEF OF COVID DEMOCRATS BY-THE-NUMBERS IS DROPPING OF JAWS
Pfizer and BioNTech
The Comirnaty vaccine from Pfizer and BioNTech, the first to receive an emergency use authorization from the FDA in December after being considered 95% effective, currently accounts for more than 46.8 million of the total doses of vaccine administered in the United States. United States, according to the CDC.
Pfizer’s latest earnings report notes that Comirnaty’s earnings are split 50-50 with BioNTech. The companies expect the vaccine to generate revenues of approximately $ 15 billion in 2021. Pfizer and BioNTech plan to deliver up to 1.3 billion doses of the vaccine worldwide by the end of 2021. The vaccine, which requires two doses , costs $ 39 in the United States and £ 28 in the EU.
Vaccine vials Pfizer-BioNTech COVID-19 are ready to be injected into the medical team at Ichilov Hospital in Tel Aviv, Israel, Sunday, December 20, 2020. (AP Photo / Ariel Schalit)
After Comirnaty’s approval, the United States agreed to pay companies $ 1.95 billion after receiving the first 100 million doses. The agreement also allowed the federal government to purchase an additional 50 million doses. At the end of that month, Pfizer, BioNTech and the federal government reached a second agreement for another 100 million doses for the same price of $ 1.95 billion. Under the second agreement, the companies will deliver at least 70 million of the additional doses by June 30, with the remaining 30 million doses to be delivered by July 31. The government also has the option to acquire up to 400 million more. doses.
Pfizer and BioNTech also announced an agreement in November with the European Commission for 200 million doses of the vaccine to be distributed to the 27 member countries of the European Union, with the option to order an additional 100 million doses. The European Commission made this request in December, Pfizer said.
Last month, Pfizer said the European Commission reached a second agreement for 200 million additional doses, 75 million of which will be delivered in the second quarter of 2021. The total number of doses to be delivered to EU member states by the end of 2021 is now 500 million, with the potential to increase to 600 million based on the option granted in the new contract.
MARRIOTT PAYS EMPLOYEES TO GET THE COVID-19 VACCINE
Modern
Moderna’s mRNA-1273 vaccine, the second to be approved for emergency use by the FDA after it was found to be 94.5% effective, accounts for more than 44.9 million of the total vaccine doses administered in the United States, according to with the CDC.
The company noted in its fourth quarter earnings report that it expects $ 18.4 billion in advance sales of products related to advance purchase agreements for its vaccine. Moderna continues on track to deliver the first 100 million doses in the first quarter of 2021 and the second order for 100 million doses in May 2021. The company aims to increase the supply of up to 1 billion doses in 2021 and 1 , 4 billion doses in 2022.
The boxes containing the Modern COVID-19 vaccine are ready to be shipped to McKesson Distribution Center in Olive Branch, Mississippi, Sunday, December 20, 2020. (AP Photo / Paul Sancya, Pool)
Moderna signed an agreement with the United States for 300 million doses, with an option to purchase an additional 200 million doses. In addition, the company closed deals with the European Union (310 million doses with the option to purchase an additional 150 million doses in 2022), Japan (50 million doses), Canada (44 million doses), Republic of Korea ( 40 million doses), United Kingdom (17 million doses), Switzerland (13.5 million doses), Colombia (10 million doses), Israel (6 million doses) and Taiwan (5 million doses).
Moderna charges $ 30 for the two doses required in the U.S. and $ 36 in the EU
GET FOX BUSINESS ON THE MOVE BY CLICKING HERE
The Johnson & Johnson vaccine, manufactured by its pharmaceutical subsidiary Janssen, received an emergency use authorization from the FDA on February 27 and an official seal of approval from the CDC a day later.
According to an FDA analysis, the Janssen vaccine was about 67% effective in preventing moderate to severe cases within 14 days after administration and 66% effective against severe to critical cases after 28 days. In addition, the vaccine was approximately 77% effective in preventing severe or critical COVID-19 occurring at least 14 days after vaccination and 85% effective in preventing severe or critical COVID-19 occurring at least 28 days after vaccination .
Boxes containing Johnson & Johnson’s COVID-19 vaccine are next to vials at the National Jewish Hospital pharmacy for distribution early on Saturday, March 6, 2021, in eastern Denver. The volunteers worked with nurses and doctors at National Jewis
The company is currently working to deliver its initial supply of 3.9 million doses of vaccine to state health departments, pharmacies, federally qualified health centers and community vaccination centers across the country. Johnson & Johnson expects to deliver enough single-dose vaccines by the end of March to vaccinate more than 20 million Americans, and 100 million single-dose vaccines by June. Unlike the other two vaccines available, the Janssen vaccine requires a single dose.
The company is on track to produce 1 billion doses for global distribution by the end of 2021, which would generate up to $ 10 billion. In August, Johnson & Johnson struck a deal of more than $ 1 billion with the United States for 100 million doses of its vaccine, with an option to purchase an additional 200 million doses for $ 10 an injection. In addition, Johnson & Johnson has reached an agreement with the EU for up to 400 million doses.
CLICK HERE TO READ MORE ABOUT FOX BUSINESS
According to Johns Hopkins University, the United States has surpassed 29 million cases of COVID-19 since the pandemic began in March 2020, with more than 525,000 related deaths.